Literature DB >> 9100317

Linking etiologies in humans and animal models: studies of autism.

P M Rodier1, J L Ingram, B Tisdale, V J Croog.   

Abstract

Thalidomide has been shown to lead to a high rate of autism when exposure occurs during the 20th to 24th d of gestation. Both the critical period and the neurological deficits of the autistic cases indicate that they have sustained injuries to the cranial nerve motor nuclei. To determine whether such lesions characterize other cases of autism, the brain stem of an autistic case was compared to that of a control. The autopsy case showed abnormalities predicted by the thalidomide cases and evidence of shortening of the brain stem, a defect that could have occurred only during neural tube closure. To test whether animals can be similarly injured but remain viable, rats were treated with 350 mg/kg of valproic acid on day 11.5, 12, or 12.5 of gestation. Neuron counts showed reductions of cell numbers in the cranial nerve motor nuclei. Rats with motor neuron deficits also had cerebellar anomalies like those reported in studies of autistic cases, supporting the idea that these animals may be a useful model of the developmental injury that initiates autism.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9100317     DOI: 10.1016/s0890-6238(97)80001-u

Source DB:  PubMed          Journal:  Reprod Toxicol        ISSN: 0890-6238            Impact factor:   3.143


  58 in total

1.  Receptive communication in late-stage Rett syndrome: a cautionary note.

Authors:  K A Meyer; C H Kennedy; S Shukla; L S Cushing
Journal:  J Autism Dev Disord       Date:  1999-02

2.  Elevated NMDA receptor levels and enhanced postsynaptic long-term potentiation induced by prenatal exposure to valproic acid.

Authors:  Tania Rinaldi; Karina Kulangara; Katia Antoniello; Henry Markram
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-03       Impact factor: 11.205

3.  Altered behavioral development in Nrf2 knockout mice following early postnatal exposure to valproic acid.

Authors:  Melody A Furnari; Constance Lay-Lay Saw; Ah-Ng Kong; George C Wagner
Journal:  Brain Res Bull       Date:  2014-10-20       Impact factor: 4.077

4.  In utero exposure to valproic acid changes sleep in juvenile rats: a model for sleep disturbances in autism.

Authors:  Danielle M Cusmano; Jessica A Mong
Journal:  Sleep       Date:  2014-09-01       Impact factor: 5.849

5.  Minor physical anomalies in children with autism spectrum disorders.

Authors:  Kathleen Angkustsiri; Paula Krakowiak; Billur Moghaddam; Terrance Wardinsky; Jerald Gardner; Nareg Kalamkarian; Irva Hertz-Picciotto; Robin L Hansen
Journal:  Autism       Date:  2011-05-24

6.  Beneficial Effects of Co-Ultramicronized Palmitoylethanolamide/Luteolin in a Mouse Model of Autism and in a Case Report of Autism.

Authors:  Bartolomeo Bertolino; Rosalia Crupi; Daniela Impellizzeri; Giuseppe Bruschetta; Marika Cordaro; Rosalba Siracusa; Emanuela Esposito; Salvatore Cuzzocrea
Journal:  CNS Neurosci Ther       Date:  2016-10-04       Impact factor: 5.243

Review 7.  Animal models of restricted repetitive behavior in autism.

Authors:  Mark H Lewis; Yoko Tanimura; Linda W Lee; James W Bodfish
Journal:  Behav Brain Res       Date:  2006-09-25       Impact factor: 3.332

8.  Synaptic and intrinsic balancing during postnatal development in rat pups exposed to valproic acid in utero.

Authors:  Elisabeth C Walcott; Emily A Higgins; Niraj S Desai
Journal:  J Neurosci       Date:  2011-09-14       Impact factor: 6.167

Review 9.  Pre-clinical models of neurodevelopmental disorders: focus on the cerebellum.

Authors:  Alexey V Shevelkin; Chinezimuzo Ihenatu; Mikhail V Pletnikov
Journal:  Rev Neurosci       Date:  2014       Impact factor: 4.353

10.  Blockage of VIP during mouse embryogenesis modifies adult behavior and results in permanent changes in brain chemistry.

Authors:  Joanna M Hill; Janet M Hauser; Lia M Sheppard; Daniel Abebe; Irit Spivak-Pohis; Michal Kushnir; Iris Deitch; Illana Gozes
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.